Paratek Pharmaceuticals, Inc., Boston, MA 02111, USA.
Infect Immun. 2010 Nov;78(11):4683-90. doi: 10.1128/IAI.01305-09. Epub 2010 Sep 7.
LcrF (VirF), a transcription factor in the multiple adaptational response (MAR) family, regulates expression of the Yersinia type III secretion system (T3SS). Yersinia pseudotuberculosis lcrF-null mutants showed attenuated virulence in tissue culture and animal models of infection. Targeting of LcrF offers a novel, antivirulence strategy for preventing Yersinia infection. A small molecule library was screened for inhibition of LcrF-DNA binding in an in vitro assay. All of the compounds lacked intrinsic antibacterial activity and did not demonstrate toxicity against mammalian cells. A subset of these compounds inhibited T3SS-dependent cytotoxicity of Y. pseudotuberculosis toward macrophages in vitro. In a murine model of Y. pseudotuberculosis pneumonia, two compounds significantly reduced the bacterial burden in the lungs and afforded a dramatic survival advantage. The MAR family of transcription factors is well conserved, with members playing central roles in pathogenesis across bacterial genera; thus, the inhibitors could have broad applicability.
LcrF(VirF)是多重适应反应(MAR)家族中的一个转录因子,调节耶尔森氏菌 III 型分泌系统(T3SS)的表达。耶尔森氏菌假结核 lcrF 缺失突变体在组织培养和感染动物模型中表现出毒力减弱。针对 LcrF 的靶向治疗为预防耶尔森氏菌感染提供了一种新的抗毒力策略。在体外测定中,筛选了小分子文库以抑制 LcrF-DNA 结合。所有这些化合物都没有内在的抗菌活性,对哺乳动物细胞也没有表现出毒性。其中一部分化合物抑制了耶尔森氏菌假结核在体外对巨噬细胞的 T3SS 依赖性细胞毒性。在耶尔森氏菌假结核肺炎的小鼠模型中,两种化合物显著降低了肺部的细菌负荷,并提供了显著的生存优势。MAR 家族的转录因子高度保守,其成员在细菌属的发病机制中发挥着核心作用;因此,这些抑制剂可能具有广泛的适用性。